Royalty Report: Drugs, Arthritis, Disease – Collection: 256265

$150.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 6

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 6

Primary Industries

  • Drugs
  • Arthritis
  • Disease
  • Therapeutic
  • Pharmaceuticals
  • Proteins
  • Autoimmune

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 256265

License Grant
The Licensor of Germany grants to the Licensee of Iceland the following Licenses and rights:
–   regarding patents:
–  –   an exclusive License for the Territory to perform research, to make, have made, develop, sell, have sold and use the Compound in the Field.
–  –   an exclusive License for the Territory, to develop, to register, to make, have made, use, import, sell and have sold Products in the Field.
–  regarding Know-How:
–  –  an exclusive License for the Territory to make, have made, develop, sell, have sold and use the Compound and Product in the Field.
License Property
The licensed compound is the pharmaceutically active compound R-(-)-2-[4-quinolin-2-yl-methoxy)-phenyl]-2-cyclopentyl acetic acid] having the molecular formula C23H23N03.  The products are any that incorporate the compound.
Field of Use
The Field shall mean the use of Product for the inhibition of leukotrienes in humans in connection with the prevention or treatment of any condition or indication, e.g. for treatment of inflammatory diseases such as Asthma, rheumatoid arthritis and inflammatory Bowel disease, etc.

IPSCIO Record ID: 245716

License Grant
The Swiss Licensor grants to the UK Licensee a worldwide, exclusive license, including the right to grant sublicenses, under the Licensed Patents, for Licensee and its Affiliates to research, develop, make, have made, use, offer for sale, sell, have sold and import Licensed Products for any and all uses in the Field in the Territory.
License Property
The nti-IL6R antibodies marketed or in development for a range of inflammatory conditions including rheumatoid arthritis. The Licensee intends to explore the development of NI-1201 in Non-alcoholic Steato hepatitis (NASH), diabetes and other life threatening inflammatory diseases.
Field of Use
Field means any and all uses including all therapeutic uses.  Licensed IP includes the nti-IL6R antibodies for a range of inflammatory conditions including rheumatoid arthritis.

Licensee desires to obtain an exclusive license to patents owned or controlled by Licensor, a sublicense to certain patents licensed from Bristol-Myers Squibb Company (“BMS”), along with any associated know-how, biologic materials, clinical data or other technology relating to IL-6 receptor monoclonal antibodies (identified as NI-1201), and their use in order to research, develop and commercialize products and services.

IPSCIO Record ID: 26633

License Grant
Licensor hereby grants to Licensee for the term, an exclusive, milestone and royalty-bearing License to the Patent (5,288,751) Rights and Licensed Technology to research, develop, make, have made, use, offer to sell, sell, and import/export Licensed Products in the Field, in the territory, subject to a non-transferable right by the Licensor and its Affiliates to utilize the Compound for internal research purposes and derivatization of new compounds.
Field of Use
Field means the treatment and/or prevention of diseases in humans.

IPSCIO Record ID: 227285

License Grant
The English parties agree to a collaboration for the further development, manufacture and commercialization of the Product initially for the treatment of rheumatoid arthritis (‘RA’) and Crohn’s disease in humans and for the treatment of any other agreed indications in the Field.  The co-exclusive collaboration includes the right to appoint any third party including but not limited to affiliated companies as distributors, except for Japan where Licensee shall have the right to appoint sub-licensees.
License Property
Product means Licensor’s anti-TNFµ compound known as CDP-870 in any formulation and indication.
Field of Use
The licence is exclusive for rheumatoid arthritis and other indications, excluding Crohn's disease.

IPSCIO Record ID: 283821

License Grant
In the Territory, the Swiss Licensor grants to the Licensee of the Cayman Islands an exclusive, including with regard to Licensor and its Affiliates, but excluding any non-exclusive license granted to Another Party by operation of  Another Development and License Agreement license, with the right to grant sublicenses to Sublicensees, under Licensor Intellectual Property and Know-How; and an exclusive, including with regard to Licensor and its Affiliates sublicense, with the right to grant sub-sublicenses to Sub-sublicensees, under Sublicensed Intellectual Property, to research, develop, make, have made, import, use, sell and offer to sell the Licensed Compound and the Licensed Product in the Field in the Territory.

For the Option Right of  the Licensee to the Optional Territory Licensor grants a non-exclusive option right to obtain an exclusive license, with the right to grant sublicenses to Sublicensees, under Licensor Intellectual Property and Know-How; and a non-exclusive option right to obtain an exclusive sublicense, with the right to grant sub-sublicenses to Sub-sublicensees, under Sublicensed Intellectual Property, to research, develop, make, have made, import, use, sell and offer to sell the Licensed Product in the Field in the mutually agreed upon countries in the Optional Territory,

License Property
Licensor has an exclusive license to certain Sublicensed Intellectual Property and certain Intellectual Property and Know-How with respect to the Licensed Compound and the Licensed Product.

Licensed Compound means FE301, i.e., SGP130Fc fusion protein, an interleukin-6 inhibitor.

The patents are for FE301 composition; FE301 dosing; Fusion proteins comprising two soluble gp130 molecules; Optimized nucleotide sequences encoding sgp130; and Improved sgp130Fc dimers.

Optimized nucleotide sequences encoding sgp130: Patent No. 8,206,948
Olamkicept is a new recombinant protein inhibitor of the interleukin-6 pathway. Interleukin-6 is associated with numerous inflammatory conditions such as inflammatory bowel diseases (IBD) and rheumatoid arthritis.

Field of Use
Field means any indication for medicinal use in humans, including rheumatoid arthritis.

IPSCIO Record ID: 76567

License Grant
We have a worldwide license and collaboration agreement which provides us the development and commercialization rights to its Janus tyrosine kinase inhibitor compound, now known as baricitinib, and certain follow-on compounds, for the treatment of inflammatory and autoimmune diseases.
Field of Use
This agreement pertains to the drug industry relating to inflammatory and autoimmune diseases.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.